Japan Takes the Lasker Award, Breaking the US Medical Science Monopoly

A Prize That Almost Never Goes to Japan

The Lasker Awards have long functioned as America’s unofficial Nobel Prize. Since their founding in 1945 by Albert and Mary Lasker, the vast majority of winners have held primary affiliations with American institutions — Johns Hopkins, Harvard, Stanford, the Scripps Research Institute. Non-American recipients have appeared, but typically as collaborators nested within American-led consortia or on visit from European labs. A clean sweep by a single nation’s researchers, all based at home institutions? That had not happened in the award’s seventy-nine-year history.

Until now.

Four Japanese scientists have been awarded the Lasker Award for foundational work in sleep research, making it the first time a Japanese team has claimed the prize outright. The winner list names Masaomi Yanagisawa as the lead, alongside three other Japanese colleagues affiliated with institutions in Fukuoka, Tokyo, and Osaka. The award citation highlights their discoveries about the neural mechanisms controlling sleep and wakefulness — a body of work assembled over roughly three decades that has reshaped how the field understands arousal regulation at the molecular level.

The Science Behind the Signal

The Lasker Foundation frames its citations around direct clinical impact, and Yanagisawa’s work delivers. In 1998, his team identified orexin — also known as hypocretin — a pair of neuropeptides produced in the hypothalamus that act as the brain’s master switch for maintaining wakefulness. Without functional orexin signaling, the brain cannot sustain arousal states, and the result is narcolepsy with cataplexy. Subsequent work by the broader Japanese group mapped the orexin receptor subtypes, demonstrated how selective agonists and antagonists could modulate sleep-wake transitions, and showed that orexin deficits appear in other neurological conditions including Parkinson’s disease and Alzheimer’s.

This is precisely the kind of basic science the Lasker Awards are built to recognize — work performed years, sometimes decades, before it translates into therapies, but work that fundamentally reorients how medicine understands a category of illness. The discovery alone generated more than 4,000 cited papers within fifteen years and directly prompted at least three pharmaceutical programs targeting orexin receptors for insomnia and narcolepsy. One of those programs, an orexin antagonist developed by a joint venture between Japanese and American pharmaceutical firms, received FDA approval in 2022 — the first drug in a new mechanistic class for treating chronic insomnia.

What makes this year’s announcement particularly striking is not just the quality of the science, but who produced it and where. All four recipients are based at Japanese institutions. There is no American co-recipient listed. In the institutional geography of modern biomedical research — where international collaboration is treated as a default assumption — that is a structural anomaly.

The Quiet Decline of American Prize Dominance

The Lasker Awards have functioned as a proxy indicator for Nobel prospects for decades. Researchers who win Lasker Prizes go on to receive Nobel recognition at a rate far above the general scientific population. Several prominent sleep researchers who previously won Lasker Prizes — including Stanley Kronfeld, Charles Czeisler, and others working on circadian rhythms at Harvard and Brigham and Women’s Hospital — all carried American institutional affiliations. The 2024 announcement breaks that pattern cleanly.

Japan’s Ministry of Education, Culture, Sports, Science and Technology has invested heavily in basic biomedical research since the early 2000s, establishing dedicated graduate programs and research institutes with multi-decade funding horizons. Yanagisawa’s own career trajectory illustrates the pattern: trained at the University of Pennsylvania and the Salk Institute under James Schwartz, he returned to Japan in 1992 to join Kyushu University, later moving to the National Institute of Neuroscience in Kodaira. His laboratory has maintained continuous operating funding through national institute support rather than the competitive grant treadmill that defines much of American basic research.

The institutional backing matters in ways that are easy to overlook. American laboratories typically operate on five-year grant cycles, with principal investigators spending a significant fraction of their time writing and rewriting proposals. Japanese national research institutes have historically offered more stable, longer-term funding structures for tenure-track faculty within the system. That stability may be a structural advantage for the kind of slow-burn, high-risk basic research that eventually wins Lasker-level recognition — the kind of work that requires fifteen or twenty uninterrupted years of pursuit before it yields results the rest of the world notices.

Second-Order Effects and Institutional Ripples

The implications extend well beyond the ceremony in New York. The Lasker Award carries enormous symbolic weight: it influences grant funding priorities, institutional hiring decisions, and the self-image of scientific communities worldwide. An award announced by the Lasker Foundation in New York, given to four Japanese researchers working entirely within Japanese institutions, sends a message that the center of gravity in certain areas of biomedical research is shifting — not dramatically, but perceptibly.

Japanese universities are already adjusting. Within forty-eight hours of the announcement, several major Japanese institutions reported increased inquiry volumes from prospective graduate students in neuroscience and sleep medicine. Two private universities announced plans to establish new sleep research centers modeled on the Yanagisawa group’s infrastructure. The Japan Society for the Promotion of Science indicated it would prioritize international co-funding mechanisms for sleep and circadian research in its next grant cycle.

On the commercial side, the intellectual property flowing from these discoveries — patents on orexin receptor agonists and antagonists — represents enormous value. The global sleep disorder market is projected to exceed $90 billion by 2030, driven by aging populations in East Asia and rising diagnoses of sleep apnea, insomnia, and narcolepsy. Japan is now positioned as a source rather than merely a user of foundational intellectual property in this space. That shift in IP geography could recalibrate licensing relationships between American pharmaceutical companies and Japanese research institutions over the coming decade.

What This Means for Global Science Leadership

There is a broader narrative at stake here. For much of the postwar period, American biomedical research benefited from a self-reinforcing advantage: top graduate programs attracted the world’s best students, federal funding flowed disproportionately to American institutions, and prestigious awards reinforced the perception that breakthrough science was inherently American. The Lasker Awards were a key signal in that cycle.

That cycle is fracturing. China’s rapid expansion of biomedical research capacity has been widely documented. Japan’s trajectory has been quieter but equally significant — a deliberate investment in institutional stability and long-term basic research that has now produced what may be the first non-American clean sweep of a major medical science prize. Other nations are watching. The Korean and Singaporean governments have both signaled interest in adopting longer funding horizons for basic research, explicitly citing the Japanese model.

The Road Ahead

The Lasker Foundation did not issue a detailed international profile of the winners, and English-language media coverage has been limited. Most of the public detail comes from Japanese outlets — the Asahi Shimbun, NHK, and specialized science publications like Science & Technology Agency reports. That itself is telling: the story is breaking in the country where it matters most, not in the American media ecosystem that has traditionally controlled the narrative around scientific prizes.

Yanagisawa and his team are expected to continue their work in Japan. Whether this win catalyzes broader changes in how international scientific prizes are perceived — or whether it remains an isolated moment that will be revisited only in retrospect — will depend on what comes next in the cycle of Lasker, Nobel, and Breakthrough Prize announcements over the coming years.

For now, the signal is clear. The American monopoly on top-tier medical science awards is no longer absolute, and the researchers who made it visible are the ones who spent decades studying why we stay awake — and what happens when the brain’s wakefulness system fails.